What is William Blair’s Estimate for PRCT FY2024 Earnings?

PROCEPT BioRobotics Co. (NASDAQ:PRCT) – William Blair raised their FY2024 earnings per share (EPS) estimates for PROCEPT BioRobotics in a research report issued to clients and investors on Monday, October 28th. William Blair analyst B. Vazquez now expects that the company will post earnings per share of ($1.74) for the year, up from their previous estimate of ($1.89). The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.88) per share. William Blair also issued estimates for PROCEPT BioRobotics’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($1.22) EPS and FY2026 earnings at ($0.63) EPS.

PRCT has been the topic of several other reports. Piper Sandler reiterated an “overweight” rating and issued a $75.00 price target on shares of PROCEPT BioRobotics in a research note on Tuesday, October 8th. TD Cowen increased their price target on shares of PROCEPT BioRobotics from $75.00 to $99.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Truist Financial reiterated a “buy” rating and issued a $105.00 target price (up previously from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday. Wells Fargo & Company raised their price target on shares of PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, Bank of America lifted their price target on shares of PROCEPT BioRobotics from $80.00 to $94.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $88.40.

PROCEPT BioRobotics Stock Performance

PRCT stock opened at $93.03 on Thursday. PROCEPT BioRobotics has a twelve month low of $24.91 and a twelve month high of $99.34. The company has a quick ratio of 6.49, a current ratio of 7.51 and a debt-to-equity ratio of 0.20. The company has a market cap of $4.83 billion, a P/E ratio of -47.71 and a beta of 1.03. The business’s fifty day moving average is $77.01 and its 200-day moving average is $67.73.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Monday, October 28th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.09. The firm had revenue of $58.40 million during the quarter, compared to analysts’ expectations of $53.30 million. PROCEPT BioRobotics had a negative return on equity of 37.85% and a negative net margin of 58.73%. PROCEPT BioRobotics’s quarterly revenue was up 66.4% compared to the same quarter last year. During the same period last year, the business earned ($0.51) earnings per share.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in PRCT. Vanguard Group Inc. increased its holdings in PROCEPT BioRobotics by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 4,184,585 shares of the company’s stock worth $175,376,000 after purchasing an additional 109,694 shares in the last quarter. Diversified Trust Co boosted its stake in PROCEPT BioRobotics by 25.4% during the first quarter. Diversified Trust Co now owns 13,442 shares of the company’s stock worth $664,000 after acquiring an additional 2,725 shares in the last quarter. Principal Financial Group Inc. grew its holdings in PROCEPT BioRobotics by 98.2% in the first quarter. Principal Financial Group Inc. now owns 20,983 shares of the company’s stock worth $1,037,000 after purchasing an additional 10,395 shares during the period. SpiderRock Advisors LLC bought a new stake in PROCEPT BioRobotics in the first quarter valued at $307,000. Finally, Essex Investment Management Co. LLC raised its holdings in shares of PROCEPT BioRobotics by 0.6% during the first quarter. Essex Investment Management Co. LLC now owns 60,116 shares of the company’s stock valued at $2,971,000 after purchasing an additional 336 shares during the period. 89.46% of the stock is owned by institutional investors.

Insider Transactions at PROCEPT BioRobotics

In related news, Director Antal Rohit Desai sold 35,220 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $76.12, for a total transaction of $2,680,946.40. Following the completion of the transaction, the director now directly owns 23,963 shares of the company’s stock, valued at $1,824,063.56. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other PROCEPT BioRobotics news, Director Antal Rohit Desai sold 35,220 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $76.12, for a total transaction of $2,680,946.40. Following the completion of the transaction, the director now owns 23,963 shares in the company, valued at approximately $1,824,063.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kevin Waters sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $72.47, for a total transaction of $1,811,750.00. Following the completion of the transaction, the chief financial officer now owns 96,096 shares in the company, valued at $6,964,077.12. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 179,892 shares of company stock worth $13,946,415. Company insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).